Premium Nahrungsergänzungsmittel | artgerecht

Elvitegravir: HIV Drug, Mechanism & Use

Elvitegravir is an antiretroviral medication used to treat HIV-1 infection. It belongs to the class of integrase inhibitors and is always used as part of combination therapy.

Regular tips about health Regular tips about health

Things worth knowing about "Elvitegravir"

Elvitegravir is an antiretroviral medication used to treat HIV-1 infection. It belongs to the class of integrase inhibitors and is always used as part of combination therapy.

What is Elvitegravir?

Elvitegravir (abbreviated: EVG) is an antiretroviral drug belonging to the class of integrase strand transfer inhibitors (INSTIs). It is used in the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults and in pediatric patients above a certain body weight. Elvitegravir is not marketed as a standalone drug; it is exclusively available in fixed-dose combination products together with other antiretroviral agents.

Indication

Elvitegravir is indicated for the treatment of HIV-1 infection as part of antiretroviral combination therapy (ART). It is a component of several approved fixed-dose combinations, including:

Stribild®: Elvitegravir + Cobicistat + Emtricitabine + Tenofovir Disoproxil Fumarate
Genvoya®: Elvitegravir + Cobicistat + Emtricitabine + Tenofovir Alafenamide

These combinations allow for a complete antiretroviral regimen in a single tablet taken once daily, significantly improving patient adherence to therapy.

Mechanism of Action

HIV requires the enzyme integrase to insert its viral DNA into the genetic material of the human host cell. Elvitegravir selectively inhibits this process by blocking the strand transfer reaction of the integrase enzyme. As a result, viral DNA cannot be integrated into the human genome, viral replication is interrupted, and the viral load in the blood decreases. Because elvitegravir is rapidly metabolized in the body, it is always co-administered with the pharmacokinetic booster cobicistat, which slows the breakdown of elvitegravir and ensures adequate plasma levels throughout the day.

Dosage and Administration

Elvitegravir is administered in the form of the above-mentioned fixed-dose combination tablets, taken orally once daily. The tablet should always be taken with food, as food significantly improves the absorption of the drug. The precise dosage depends on the specific combination product and the individual condition of the patient. Special caution is required in patients with reduced kidney function, as some of the co-administered agents can affect renal function.

Side Effects

Elvitegravir is generally well tolerated. The most commonly reported side effects associated with its combination products include:

Nausea and diarrhea
Headache
Fatigue and dizziness
Elevated serum creatinine levels (caused by the booster cobicistat, without true impairment of kidney function)
Changes in blood lipid levels

Rarer but more serious adverse effects can include lactic acidosis (a build-up of lactic acid in the blood) or hepatic steatosis (fatty liver), particularly when tenofovir disoproxil fumarate is used as a co-component.

Drug Interactions

Because elvitegravir is co-administered with the CYP3A4 inhibitor cobicistat, there are numerous potential drug interactions. Cobicistat inhibits several hepatic enzymes (primarily CYP3A4), which affects the metabolism of many other medications. Patients should always inform their doctor or pharmacist about all medications, supplements, and herbal products they are taking. Certain drugs (e.g., rifampicin, St. John's Wort, some antiepileptics) are contraindicated, as they can significantly reduce the efficacy of elvitegravir.

Therapeutic Context

Elvitegravir-containing regimens are considered effective and well tolerated for treatment-naive patients as well as for certain treatment-experienced patients without relevant resistance mutations. The once-daily single-tablet regimen promotes adherence, which is critical for long-term treatment success. Regular monitoring (viral load, CD4 cell count, renal function) is essential throughout the course of therapy.

References

European Medicines Agency (EMA): Genvoya - Summary of Product Characteristics. Available at: www.ema.europa.eu
European Medicines Agency (EMA): Stribild - Summary of Product Characteristics. Available at: www.ema.europa.eu
EACS European AIDS Clinical Society: Guidelines Version 12.0, 2023. Available at: www.eacsociety.org

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.